A Breakthrough in Depression Treatment
For decades, people with treatment-resistant depression have faced limited options after oral antidepressants failed. Now, a large clinical trial published in JAMA Psychiatry shows that esketamine nasal spray for treatment-resistant depression can work effectively as a standalone treatment, offering rapid relief—sometimes within 24 hours.
Esketamine, a chemical cousin of ketamine, is the active ingredient in the FDA-approved nasal spray SPRAVATO®. Unlike traditional antidepressants, which can take weeks to take effect, esketamine targets the brain in a different way, producing fast-acting changes in mood and symptoms.
Why This Matters for Patients
About one in three people with major depressive disorder do not respond to standard antidepressants. This group, defined as having treatment-resistant depression, often experiences side effects such as fatigue, weight gain, and sexual dysfunction from medications. These side effects not only cause distress but also make it difficult for patients to stick with treatment.
Esketamine nasal spray offers a different path. By using esketamine alone, patients may no longer need to rely on multiple oral drugs, reducing both side effects and treatment complexity.
Inside the Clinical Trial
The trial included nearly 400 adults with moderate to severe depression who had failed at least two oral antidepressants. Participants stopped their previous medications and were randomly assigned to receive either esketamine (at two different doses) or a placebo spray, twice a week for four weeks.
Results showed that both doses of esketamine led to significantly greater improvements in depression scores compared to placebo. Remarkably, many participants experienced meaningful changes in mood within the first 24 hours.
Those who continued into the study’s open-label phase (where everyone received esketamine) often showed continued improvement, suggesting that the benefits may last beyond the initial four weeks.
Safety and Side Effects
As with past studies, esketamine treatment was associated with short-lived side effects like nausea, dizziness, headache, and dissociation—a temporary feeling of detachment. These typically resolved within a few hours after dosing and were monitored under medical supervision. Importantly, no new safety concerns were identified in the study.
All patients receiving SPRAVATO® must be monitored in a certified clinic for at least two hours after each session, ensuring both safety and proper follow-up care.
What Comes Next
While the results are promising, researchers emphasize that more work is needed to confirm long-term safety and identify which patients benefit the most. The trial also highlighted the need for more diverse study samples to ensure broader applicability.
Still, this research marks a milestone in psychiatric treatment. For the first time, esketamine nasal spray for treatment-resistant depression is proven to be effective as a single-agent therapy, opening the door for new strategies in mental health care.
Esketamine nasal spray is reshaping the landscape of depression treatment. By providing rapid relief as a standalone therapy, it offers new hope to patients who have struggled with limited options and lengthy waits for improvement. This innovation could transform how clinicians approach treatment-resistant depression in the years ahead.
References
- Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment‑Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Published July 2, 2025. doi:10.1001/jamapsychiatry.2025.1317 tribemd.com+3consultant360.com+3pubmed.ncbi.nlm.nih.gov+3
- U.S. Food and Drug Administration. SPRAVATO® (esketamine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf